科倫藥業(002422.SZ)：子公司川寧生物建設的工程技術中心通過驗收
格隆匯1月19日丨科倫藥業(002422.SZ)公佈，2021年1月19日，公司控股子公司伊犁川寧生物技術股份有限公司(“川寧生物”)收到中華人民共和國生態環境部(“生態環境部”)《關於同意國家環境保護抗生素菌渣無害化處理與資源化利用工程技術中心通過驗收的通知》(環科財函【2021】3號)，川寧生物建設的“國家環境保護抗生素菌渣無害化處理與資源化利用工程技術中心”(“工程技術中心”)通過了生態環境部驗收。
工程技術中心於2018年1月10日經生態環境部(原國家環境保護部)批准，依託川寧生物開展建設，建設期兩年。工程技術中心的主要任務是：結合我國抗生素原料藥生產現狀及特點，以我國抗生素菌渣污染控制、改善環境質量為目標，開展抗生素菌渣無害化處理與資源化利用技術的創新、融合和系統集成，突破抗生素菌渣無害化處理與資源化利用領域的關鍵技術和共性技術，通過工程化加以推廣應用，推動我國抗生素原料藥生產行業的健康可持續發展。
工程技術中心在生態環境部的指導下，緊緊圍繞中心任務和發展目標，經過近3年建設，建成了抗生素菌渣無害化處理與資源化利用領域的研發、試驗場地，配套了相關硬件設施，與國內外相關高校、科研院所和行業組織建立了合作關係，具備了良好的技術研發能力。工程技術中心在抗生素菌渣高温水解、噴霧乾燥、電子束輻照、生物酶法等無害化處理與資源化利用等方面開展了技術研發和工程化驗證與示範，形成了一批新技術、新裝備，成果轉化及產業化效果顯著，取得了良好的社會效益和環境效益。
工程技術中心將在通過生態環境部驗收的基礎上，按照生態環境部的要求，進一步加大產學研用合作，突出核心關鍵技術的研發與應用，加強對行業的輻射和帶動，充分發揮工程技術中心對國家環境管理和環境治理的技術支撐作用，助推行業綠色、低碳、可持續健康發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
